441 related articles for article (PubMed ID: 22458756)
21. Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Einarson TR; Pudas H; Goswami P; van Impe K; Bereza BG
J Med Econ; 2016; 19(2):111-20. PubMed ID: 26414966
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.
Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A;
Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869
[TBL] [Abstract][Full Text] [Related]
23. Paliperidone palmitate versus oral risperidone and risperidone long-acting injection in patients with recently diagnosed schizophrenia: a tolerability and efficacy comparison.
Fu DJ; Bossie CA; Sliwa JK; Ma YW; Alphs L
Int Clin Psychopharmacol; 2014 Jan; 29(1):45-55. PubMed ID: 24113628
[TBL] [Abstract][Full Text] [Related]
24. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs.
Yang YK; Tarn YH; Wang TY; Liu CY; Laio YC; Chou YH; Lee SM; Chen CC
Psychiatry Clin Neurosci; 2005 Aug; 59(4):385-94. PubMed ID: 16048443
[TBL] [Abstract][Full Text] [Related]
25. Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.
Lafeuille MH; Grittner AM; Fortier J; Muser E; Fasteneau J; Duh MS; Lefebvre P
Am J Health Syst Pharm; 2015 Mar; 72(5):378-89. PubMed ID: 25694413
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA.
Edwards NC; Locklear JC; Rupnow MF; Diamond RJ
Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain.
Einarson TR; Bereza BG; Garcia Llinares I; González Martín Moro B; Tedouri F; Van Impe K
J Med Econ; 2017 Oct; 20(10):1039-1047. PubMed ID: 28678566
[TBL] [Abstract][Full Text] [Related]
28. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Park T; Kuntz KM
Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
[TBL] [Abstract][Full Text] [Related]
30. A cost-effectiveness clinical decision analysis model for schizophrenia.
Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
[TBL] [Abstract][Full Text] [Related]
31. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model.
Vera-Llonch M; Delea TE; Richardson E; Rupnow M; Grogg A; Oster G
Value Health; 2004; 7(5):569-84. PubMed ID: 15367252
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US.
Edwards NC; Rupnow MF; Pashos CL; Botteman MF; Diamond RJ
Pharmacoeconomics; 2005; 23(3):299-314. PubMed ID: 15836010
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China.
Yang L; Li M; Tao LB; Zhang M; Nicholl MD; Dong P
Value Health; 2009; 12 Suppl 3():S66-9. PubMed ID: 20586985
[TBL] [Abstract][Full Text] [Related]
34. Cost effectiveness of long-acting risperidone in Sweden.
Hensen M; Heeg B; Löthgren M; van Hout B
Appl Health Econ Health Policy; 2010; 8(5):327-41. PubMed ID: 20804225
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
[TBL] [Abstract][Full Text] [Related]
37. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
[TBL] [Abstract][Full Text] [Related]
38. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda.
Lubinga SJ; Mutamba BB; Nganizi A; Babigumira JB
Appl Health Econ Health Policy; 2015 Oct; 13(5):493-506. PubMed ID: 25958192
[TBL] [Abstract][Full Text] [Related]
39. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.
Li H; Rui Q; Ning X; Xu H; Gu N
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jun; 35(4):1002-8. PubMed ID: 21315787
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of olanzapine and risperidone in Norway.
Kim K; Aas E
J Ment Health Policy Econ; 2011 Sep; 14(3):125-35. PubMed ID: 22116170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
